In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Appropriations bill

This article was originally published in The Tan Sheet

Executive Summary

A resolution to the Agriculture, Rural Development, FDA & Related Agencies Appropriations bill for fiscal 2006 mandates that members of FDA advisory committees disclose conflicts of interest no later than 15 days prior to meetings in order to receive waivers, according to a House conference report issued Oct. 28. Congress approved a measure by Rep. Maurice Hinchey (D-N.Y.) in June that would have stopped funding for waivers, thus preventing scientists and doctors with conflicts of interest from participating on committees (1"The Tan Sheet" June 13, 2005, p. 10). The Senate revamped the language in September to approve a less stringent measure; the Senate language serves as the foundation for the conference version, which "says to the FDA...if you want to continue using doctors and scientists with conflicts of interest, go right ahead, just let us know about it," Hinchey said. "That's unacceptable"...

You may also be interested in...



FDA Panel Conflict of Interest Waivers Would Be Barred Under House Bill

FDA would effectively be barred from granting financial conflict of interest waivers for advisory committee members under the fiscal year 2006 House agriculture appropriations bill

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS098768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel